RECRUITINGOBSERVATIONAL
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
About This Trial
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
Who May Be Eligible (Plain English)
Who May Qualify:
- Provided willing to sign a consent form for the LTFU study
- Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol
Who Should NOT Join This Trial:
- Not applicable
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Provided informed consent for the LTFU study
* Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol
Exclusion Criteria:
* Not applicable
Treatments Being Tested
DRUG
KYV-101
Autologous fully-human anti-CD19 chimeric antigen receptor T-cell (CD19 CAR T) product.
Locations (1)
University of Colorado, Denver
Denver, Colorado, United States